scFv(CEA)-CD3zeta CAR-T Lentivirus

The scFv(CEA)-CD3ζ CAR-T lentivirus is a research-grade, replication-deficient lentiviral vector designed to deliver a first-generation chimeric antigen receptor targeting carcinoembryonic antigen (CEA). The core of this vector is the coupling of a high-affinity anti-CEA single-chain variable fragment (scFv) to the CD3ζ signaling domain, providing a clear and typical activation signal upon antigen binding. Built on a self-inactivating (SIN) lentiviral backbone, this system typically employs a broad-spectrum pseudotype, supporting stable genomic integration and persistent transgene expression in both dividing and non-dividing cells—characteristics particularly important for primary T cell engineering and long-term functional studies. The first-generation design intentionally excludes co-stimulatory domains, providing experimental clarity by isolating CD3ζ-mediated TCR proximal signaling; this allows researchers to precisely dissect activation thresholds, basal signaling tendencies, and downstream signaling cascades without confounding factors.

This vector is suitable for a variety of preclinical applications centered on CEA-positive malignancies, including colorectal cancer, gastric cancer, pancreatic cancer, and certain breast cancers, as well as exploring CEA expression in the solid tumor microenvironment. In vitro, it can be used to generate CEA-CAR T cells for antigen-specific cytotoxicity assessment, activation and exhaustion profiling, cytokine and chemokine measurements, target density mapping, and serial killing and persistence kinetics analysis. In vivo, the system supports mechanistic studies in xenograft models to assess tumor control, cell migration, and antigen-selective binding, and to investigate the impact of on-target/off-target effects when CEA is present in normal tissues. This vector is ideally suited for combination therapy studies with immune checkpoint blockade, cytokine support, or small molecule modulators, and can be used to evaluate the impact of hinge/transmembrane region selection, promoter strength, and signal intensity on effector function and safety.